LT3079667T - Farmacinės vaisto formos - Google Patents

Farmacinės vaisto formos

Info

Publication number
LT3079667T
LT3079667T LTEP14819084.6T LT14819084T LT3079667T LT 3079667 T LT3079667 T LT 3079667T LT 14819084 T LT14819084 T LT 14819084T LT 3079667 T LT3079667 T LT 3079667T
Authority
LT
Lithuania
Prior art keywords
pharmaceutical form
pharmaceutical
Prior art date
Application number
LTEP14819084.6T
Other languages
English (en)
Lithuanian (lt)
Inventor
Suzie RIBEIRO
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of LT3079667T publication Critical patent/LT3079667T/lt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1635Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833Encapsulating processes; Filling of capsules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
LTEP14819084.6T 2013-12-13 2014-12-11 Farmacinės vaisto formos LT3079667T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361915606P 2013-12-13 2013-12-13
PCT/IB2014/066820 WO2015087283A1 (en) 2013-12-13 2014-12-11 Pharmaceutical dosage forms

Publications (1)

Publication Number Publication Date
LT3079667T true LT3079667T (lt) 2019-09-10

Family

ID=52146563

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP14819084.6T LT3079667T (lt) 2013-12-13 2014-12-11 Farmacinės vaisto formos

Country Status (33)

Country Link
US (3) US10278969B2 (OSRAM)
EP (2) EP3079667B1 (OSRAM)
JP (2) JP6522619B2 (OSRAM)
KR (1) KR102349893B1 (OSRAM)
CN (2) CN105813635A (OSRAM)
AR (1) AR098716A1 (OSRAM)
AU (1) AU2014362999B2 (OSRAM)
CA (1) CA2930055C (OSRAM)
CL (1) CL2016001436A1 (OSRAM)
CY (1) CY1122063T1 (OSRAM)
DK (1) DK3079667T3 (OSRAM)
EA (1) EA036288B1 (OSRAM)
EC (1) ECSP16060194A (OSRAM)
ES (1) ES2745983T3 (OSRAM)
HR (1) HRP20191691T1 (OSRAM)
HU (1) HUE045156T2 (OSRAM)
IL (1) IL245705B (OSRAM)
LT (1) LT3079667T (OSRAM)
MA (1) MA39175A1 (OSRAM)
MX (1) MX2016007652A (OSRAM)
MY (1) MY194303A (OSRAM)
NZ (2) NZ719865A (OSRAM)
PE (1) PE20160851A1 (OSRAM)
PH (1) PH12016501039B1 (OSRAM)
PL (1) PL3079667T3 (OSRAM)
PT (1) PT3079667T (OSRAM)
RS (1) RS59270B1 (OSRAM)
SG (1) SG10202104627UA (OSRAM)
SI (1) SI3079667T1 (OSRAM)
TN (1) TN2016000207A1 (OSRAM)
TW (2) TWI721938B (OSRAM)
WO (1) WO2015087283A1 (OSRAM)
ZA (1) ZA201603064B (OSRAM)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014362999B2 (en) 2013-12-13 2017-10-12 Novartis Ag Pharmaceutical dosage forms
MA41611A (fr) * 2015-02-23 2018-01-02 Omthera Pharmaceuticals Inc Préparations en milli-capsules comprenant des acides gras polyinsaturés libres
EP3675827A1 (en) 2017-08-30 2020-07-08 Acadia Pharmaceuticals Inc. Formulations of pimavanserin
EP4262774A4 (en) * 2020-12-18 2024-11-13 QED Therapeutics, Inc. METHODS FOR TREATING ACHINDROPLASIA
CN117042738A (zh) * 2021-03-17 2023-11-10 埃科特莱茵药品有限公司 药物剂量系统

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
NZ591443A (en) 2005-09-22 2013-04-26 Intermune Inc Granule formation of pirfenidone and pharmaceutically acceptable excipients
CN101336237B (zh) 2005-12-21 2015-09-30 诺华股份有限公司 作为fgf抑制剂的嘧啶基芳基脲衍生物
FR2910813B1 (fr) * 2006-12-28 2009-02-06 Sanofi Aventis Sa Nouvelle utilisation therapeutique pour le traitement des leucemies
AR079257A1 (es) * 2009-12-07 2012-01-04 Novartis Ag Formas cristalinas de 3-(2,6-dicloro-3-5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas
ES2610931T3 (es) 2011-07-01 2017-05-04 Novartis Ag Terapia de combinación
AU2014287209B2 (en) 2013-07-09 2019-01-24 Dana-Farber Cancer Institute, Inc. Kinase inhibitors for the treatment of disease
AU2014362999B2 (en) 2013-12-13 2017-10-12 Novartis Ag Pharmaceutical dosage forms
KR20170060042A (ko) 2014-09-13 2017-05-31 노파르티스 아게 Alk 억제제의 조합 요법
JP2018509448A (ja) 2015-03-25 2018-04-05 ノバルティス アーゲー 組合せ医薬
CA2986441A1 (en) 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors

Also Published As

Publication number Publication date
KR102349893B1 (ko) 2022-01-10
TN2016000207A1 (en) 2017-10-06
IL245705B (en) 2021-05-31
US20200054632A1 (en) 2020-02-20
HUE045156T2 (hu) 2019-12-30
US20170007602A1 (en) 2017-01-12
JP2017502941A (ja) 2017-01-26
ECSP16060194A (es) 2019-07-31
CA2930055A1 (en) 2015-06-18
JP6522619B2 (ja) 2019-05-29
PH12016501039A1 (en) 2016-07-04
JP2019142927A (ja) 2019-08-29
US10278969B2 (en) 2019-05-07
PH12016501039B1 (en) 2024-01-19
EP3597179A1 (en) 2020-01-22
PE20160851A1 (es) 2016-09-14
HK1223833A1 (en) 2017-08-11
AU2014362999A1 (en) 2016-05-26
CL2016001436A1 (es) 2017-02-10
NZ760002A (en) 2022-07-29
CN116942629A (zh) 2023-10-27
NZ719865A (en) 2022-07-29
EP3079667A1 (en) 2016-10-19
MA39175A1 (fr) 2017-10-31
EA201691231A1 (ru) 2016-10-31
SI3079667T1 (sl) 2019-10-30
IL245705A0 (en) 2016-07-31
ES2745983T3 (es) 2020-03-04
HRP20191691T1 (hr) 2019-12-27
CY1122063T1 (el) 2020-11-25
PT3079667T (pt) 2019-10-10
DK3079667T3 (da) 2019-09-09
EA036288B1 (ru) 2020-10-22
US11160804B2 (en) 2021-11-02
TWI800759B (zh) 2023-05-01
WO2015087283A1 (en) 2015-06-18
TW202128137A (zh) 2021-08-01
TWI721938B (zh) 2021-03-21
TW201605494A (zh) 2016-02-16
AR098716A1 (es) 2016-06-08
EP3597179B1 (en) 2024-04-03
MX2016007652A (es) 2016-10-13
RS59270B1 (sr) 2019-10-31
ZA201603064B (en) 2017-07-26
KR20160096093A (ko) 2016-08-12
JP6804585B2 (ja) 2020-12-23
SG10202104627UA (en) 2021-06-29
PL3079667T3 (pl) 2020-02-28
US20220265651A1 (en) 2022-08-25
CA2930055C (en) 2023-07-04
AU2014362999B2 (en) 2017-10-12
MY194303A (en) 2022-11-27
CN105813635A (zh) 2016-07-27
EP3079667B1 (en) 2019-06-26

Similar Documents

Publication Publication Date Title
NL301345I2 (nl) datopotamab deruxtecan
FIC20240001I1 (fi) Tislelitsumabi
NL301272I2 (nl) Fezolinetant
NL301194I2 (nl) mosunetuzumab
NL301171I2 (nl) Tigolaner
NO2021043I1 (no) dostarlima
FR21C1059I2 (fr) Compositions pharmaceutiques
NO2021038I1 (no) lumasiran
DK3030262T3 (da) Kombineret farmaceutisk sammensætning
DOS2013000177S (es) Capsulas
DK3052081T3 (da) Pastil
DK3060460T3 (da) Saddel
DK3027598T3 (da) Oxoquinazolinyl-butanamidderivater
DK2956698T5 (da) Bindestrimler
PL2945641T3 (pl) Cykloalkinowe pochodne sacharydów
DK2946640T3 (da) Langmuir-probe
FR3011475B1 (fr) Descendeur-assureur autobloquant
DE102013106534B8 (de) Chromatographiepipettenspitze
NL301170I1 (nl) Somatrogon
LT3079667T (lt) Farmacinės vaisto formos
DK3003401T3 (da) Farmaceutisk præparat
HUE050917T2 (hu) Hidrokortizon-tartalmú készítmény
DE112014001252A5 (de) Aufbissschiene
HRP20171888T1 (hr) Farmaceutski pripravci
DK2981168T3 (da) Laminitiskile